Skip to main
CLYM

CLYM Stock Forecast & Price Target

CLYM Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 62%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Climb Bio is a promising biotech company with a strong pipeline and a focus on developing therapies for immune-mediated diseases. Their lead drug, Budoprutug, has shown positive results in non-human primate studies and we expect it to demonstrate similar results in its upcoming Phase 1 readout. Additionally, budo's potential dosing advantage over first-gen agents and upcoming data in primary membranous nephropathy (pMN) and immune thrombocytopenia (ITP) add to our positive outlook. With a positive safety profile and a strong cash runway, we see potential upside for Climb Bio's stock in the mid-$20s range should CLYM replicate NHP results and demonstrate a feasible extended dosing profile.

Bears say

Climb Bio is a clinical-stage biotechnology company with a potential negative outlook due to several factors. These include the potential competition from other companies with similar products, the regulatory challenges and potential delays in gaining approval, and the limited clinical data and small sample sizes for their pipeline products which may not accurately reflect their potential efficacy for treating immune-mediated diseases. Additionally, their stock has already had a significant increase this year and may face challenges in sustaining this growth without a steady stream of positive catalysts.

CLYM has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 62% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Climb Bio Inc (CLYM) Forecast

Analysts have given CLYM a Strong Buy based on their latest research and market trends.

According to 13 analysts, CLYM has a Strong Buy consensus rating as of Aug 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Climb Bio Inc (CLYM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.